Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Evaluate whether treatment with perioperative zoledronic acid prolongs overall survival or disease free survival.
研究概览
简要总结
The overall purpose of this research is to evaluate the safety and side effects of zoledronic acid (also known as Zometa) in patients before they have surgery to remove the cancer.
详细描述
Cancer of the pancreas carries an ominous prognosis. The five-year overall survival rate of this malignancy is less than 5%. Chemotherapy with gemcitabine carries a response rate of approximately 25%. Resection offers the only potential for cure; however, even with resection, the great majority of patients will die with metastatic disease. Substantial improvements are needed in the treatment of this malignancy.
Patients with this disease process have clearly developed a tolerance to their pancreatic tumor. This is evidenced by an increased number and activity immunosuppressive cells including MDSC and Treg in patients with pancreas cancer. An intervention that inhibits this population of MDSC and Treg may be highly useful in the treatment of this disease process.
A novel treatment of pancreas cancer, in this setting, would be to deplete circulating and tumor-associated immunosuppressive cells prior to resection. This would facilitate the host to mount a greater immune response against the tumor. The eventual goal would be to combine neoadjuvant zoledronic acid with gemcitabine, another agent which synergizes with zoledronic acid to target MDSC. When combined with current adjuvant chemoradiation, the use of zoledronic acid in the neoadjuvant and adjuvant setting, it is hoped that the patient could mount a greater immune response leading to increased overall survival through the prevention of local disease and distant metastasis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must have a newly diagnosed, histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma. The histological slides or blocks must be available for review.
- •Patient must have resectable disease and be a candidate for surgical treatment.
- •Recent CT scan demonstrating pancreatic tumor, no evidence of distant disease, and no contraindication to resection.
- •Patients must be ≥ 18 years old.
- •Performance Status: Karnofsky Performance Status (KPS) ≥ 70
- •Life Expectancy > 12 weeks.
- •No previous history of chemotherapy for pancreas cancer prior to the start of protocol treatment.
- •Patients must have recovered from uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia.
- •Patients must have adequate bone marrow function defined as an absolute neutrophil count >1,500/mm3, platelet count >100,000/mm3 and hemoglobin >10 g/dl.
- •Patients must have normal renal function defined as serum creatinine ≤ 1.3 mg/dl or creatinine clearance ≥ 90 ml/min/1.73 m2 with a serum creatinine > 1.3 mg/dl.
- •Patients must have adequate hepatic function with total bilirubin < 5.0 mg/dl and AST ≤ 3x the institutional normal value.
- •Patient must have no prior or current active autoimmune disease requiring management with immunosuppression. This includes inflammatory bowel disease, systemic vasculitis, scleroderma, psoriasis, hemolytic anemia, immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, sarcoidosis or other rheumatologic disease. Asthma and chronic obstructive pulmonary disease that does not require daily systemic corticosteroids is acceptable.
- •The patient with previous history of malignancy is eligible for this study only if the patient meets the following criteria for cancer survivor: (i) patient has undergone potentially curative therapy for all prior malignancies; (ii) the patient has been considered disease free for at least 5 years; (iii) adequately treated non-melanomatous skin cancer.
- •For all sexually active patients, the use of adequate barrier contraception (hormonal or barrier method of birth control) will be required during therapy, prior to study entry and for the duration of study participation. Non-pregnant status will be determined in all women of childbearing potential.
- •After being informed of the treatment involved, patients (or their legally authorized representative) must given written consent.
排除标准
- •Patient is currently receiving other investigational agents.
- •Pregnant and nursing women patients are not eligible.
- •Patients known to be HIV positive are ineligible because of the potential inability to modulate immune responses (patient self-report).
- •Patients treated with any bisphosphonate-based therapeutic for any indication, during the previous year.
- •Patients with recent (within 6 weeks) or planned dental or jaw surgery dental or jaw surgery (e.g. extraction, implants).
- •Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.
- •Patients with a history of aspirin sensitive asthma.
研究组 & 干预措施
Neoadjuvant Zoledronic Acid
Zoledronic acid 4 mg IV prior to pancreatic resection (approximately 2 weeks prior to resection)
Pancreatic resection
Zoledronic acid 4 mg IV monthly for two additional doses
干预措施: Zoledronic acid (Drug)
结局指标
主要结局
Evaluate whether treatment with perioperative zoledronic acid prolongs overall survival or disease free survival.
时间窗: 2 years
Evaluate the safety and feasibility perioperative neoadjuvant zoledronic acid in patients with resectable pancreas cancer.
时间窗: 1 year postoperatively
Rate of grade 3 and 4 toxicities, especially nephrotoxicity, electrolyte imbalance and osteonecrosis of the jaw.
次要结局
- Determine the pharmacodynamics on selected immune cell subgroups in the peripheral blood and marrow by flow cytometric analysis.(Marrow (prior to first dose of zoledronic acid and week 10), peripheral blood (prior to first dose of zoledronic acid, week 10, and month 6))
- Determine the pharmacodynamics of neoadjuvant zoledronic acid therapy on the neoangiogenesis.(Prior to zoledronic acid treatment and then completion of zoledronic acid treatment (approximately 10 weeks))
- Determine the pharmacodynamics and surrogate markers neoangiogenesis analyzed by ELISA.(Prior to zoledronic acid treatment and then completion of zoledronic acid treatment (approximately 10 weeks))
- Determine the pharmacodynamics of neoadjuvant zoledronic acid therapy on selected immune cell subgroups in the tumor microenvironment by flow cytometric analysis of pancreatic tumor samples.(Approximately week 2 (at time of surgery))
- Determine the pharmacodynamics of neoadjuvant zoledronic acid therapy on selected immune cell subgroups in the hepatic metastatic niche by flow cytometric analysis of pancreatic tumor samples(Approximately 2 weeks (time of surgery))
- Correlate the presence of micrometastatic disease with time to recurrence and outcome.(6 months postoperatively)
- Measure the change in the amount of micrometastatic disease from baseline.(6 months postoperatively)
- Measure the presence and change of micrometastatic disease present in the bone marrow at the time of surgery versus baseline using immunohistochemistry.(Baseline and week 2 (time of surgery))
- Evaluate the clinical response and time to disease progression.(6 months postoperatively)